Paul-Peter Tak is Senior Vice President (SVP) R&D Pipeline, Chair of the Development Steering Team and Chief Immunology Officer at GSK. He is global head of R&D for Oncology, ImmunoInflammation and Infectious Disease. He is also on the Board of Directors of ViiV Healthcare and Galvani Bioelectronics.
He co-chairs GSK’s Scientific Review Board, is a member of the Portfolio Investment Board, member of the Scientific Advisory Board of Medicxi (Life Sciences Fund), and member of the Innovation Board Steering Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Since 2011 he has been SVP and head of the ImmunoInflammation Therapy Area Unit (TAU) at GSK until he was promoted to SVP R&D Pipeline in 2016. In this previous role he has built the ImmunoInflammation TAU, which has become an emerging core TAU for GSK; during this time the ImmunoInflammation TAU brought 9 new mechanisms of action in the clinic and filed one medicine which was approved (Benlysta s.c.).
He is Professor of Medicine at the Academic Medical Centre of the University of Amsterdam, Honorary Professor of Rheumatology at Ghent University and Honorary Senior Visiting Fellow at the University of Cambridge.
He received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has worked in basic science at the University of California San Diego for two years. He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years. He has published extensively in peer-reviewed journals (H factor 112) and has been elected Fellow of the Academy of Medical Sciences in the U.K.
At AMC he discovered the cholinergic anti-inflammatory pathway in rheumatoid arthritis and, using a bioelectronic approach, translated this into the first successful clinical trial in an immune-mediated inflammatory disease.
In addition to his work in academia he established a biotech company developing intra-articular gene therapy (Arthrogen b.v., Amsterdam); the Canadian and Dutch regulators approved the first clinical trial with its lead compound, ART-I02, in 2017.